Crucial US Panel to Cast Ballots on Altering Newborn Hepatitis B Vaccine Guideline
Following a delay and a remarkably divisive meeting, a federal vaccine advisory panel was expected to vote on Friday on whether to change the longstanding recommendation that all newborns be vaccinated against hepatitis B.
Heated Debate and a Postponed Decision
The opening session of the meeting on Thursday was defined by heated debate over restricting access to the hepatitis B vaccine for newborns and a resolution to defer the vote by a day to allow panelists additional time to review the wording. The panel, which advises the CDC on immunization practices, had put off the vote twice in the past.
“Is there any definitive data of injury of giving this immunization before 30 days? Or is this conjecture?” inquired one adviser.
In response, another attendee stated, “There is limited evidence about the prolonged hazard.”
Current Guidelines and Likely Ramifications
The injection is currently recommended for each baby within 24 hours of being born to stop transmission of hepatitis B, which can result in serious liver damage. It has been administered to more than a billion persons for over thirty years.
The meeting in Atlanta presented no new evidence of injuries resulting from the vaccine. Authorities state any change to the present hepatitis B vaccine regimen could have profound and widespread implications for pediatric well-being in the United States.
Group Membership and Recent Changes
The consultative group can only make recommendations to the head of the CDC. The committee's composition has experienced alterations recently, with the announcement that the panel's latest chairman would leave for an formal position and be substituted with a cardiac doctor who has been skeptical about other inoculations.
The board includes several vaccination critics who are in agreement with a desire to overhaul – and potentially, in some cases, eliminate – long-established immunization guidelines.
